RetinaLogik has secured Class II medical device approval from Health Canada for its visual field exam platform.

RetinaLogik公司已获得加拿大卫生部对其视野检查平台的II类医疗器械批准。

Coming in the form of a wearable virtual reality (VR) headset, which guides patients through a range of vision tests, the company’s platform is ISO-13485 and MDSAP certified and has been registered with the US Food and Drug Administration (FDA).

该公司的平台以可穿戴虚拟现实（VR）头戴设备的形式呈现，引导患者完成各种视力测试，已通过ISO-13485和MDSAP认证，并已在美国食品药品监督管理局（FDA）注册。

Upon exam completion, AI algorithms incorporated into the platform analyse the results, assisting clinicians in identifying patterns of deterioration or improvement to help guide treatment decisions and monitor the effectiveness of interventions in eye conditions such as glaucoma.

考试完成后，平台中融入的人工智能算法会分析结果，帮助临床医生识别恶化或改善的模式，以指导治疗决策，并监测青光眼等眼部疾病干预措施的有效性。

Coinciding with the Health Canada approval, RetinaLogic has completed a C$1.1m fund raise, bringing its funding to date to around C$2m since the company’s launch in 2021.

与加拿大卫生部的批准同时，RetinaLogic已完成110万加元的融资，自2021年公司成立以来，截至目前总融资额约为200万加元。

With plans to expand the adoption of its platform across North America and beyond, RetinaLogik CEO Dr Abdullah Sarhan called the milestones a “proud moment” for the company.

RetinaLogik首席执行官阿卜杜拉·萨尔汉博士表示，随着公司计划在北美及其他地区扩大其平台的采用，这些里程碑标志着公司迎来了一个“自豪的时刻”。

“With the support of our investors and partners, we’re excited to continue growing and improving the future of eye care for everyone,” said Sarhan.

“在我们的投资者和合作伙伴的支持下，我们很高兴能够继续成长，并改善每个人的未来眼科护理，”萨尔汉说。

The round was co-led by Spring Impact Capital and the University of Calgary’s investment fund, UCeed, and included participation from existing backers Startup TNT and HaloHealth.

本轮融资由 Spring Impact Capital 和卡尔加里大学的投资基金 UCeed 共同领投，现有支持者 Startup TNT 和 HaloHealth 也参与其中。

In obtaining device approval from Health Canada, RetinaLogik received support from the Accelerating Innovations into Care (AICE) programme of Alberta Innovates, an initiative of the province’s government founded to support early-stage startups across a range of disciplines.

在获得加拿大卫生部的设备批准过程中，RetinaLogik 得到了阿尔伯塔创新机构的“加速创新融入医疗”（AICE）计划的支持，该计划由省政府发起，旨在支持各学科领域的早期初创企业。

Alberta Innovates’ health vice president Trevor Lynn commented: “This accomplishment is an example of Alberta’s success commercialising health innovation to improve the patient experience and enable easier patient care access in the community.”

阿尔伯塔创新公司健康副总裁特雷弗·林恩评论道：“这一成就展示了阿尔伯塔在商业化健康创新方面的成功，改善了患者的体验，并使社区中的患者更容易获得医疗服务。”

In other eye care news,

在其他眼科护理新闻中，

Perfuse released Phase I/IIa data

灌注发布了一期/二期数据

earlier this month indicating that its PER-001 intravitreal implant for glaucoma was well-tolerated, with only a single, mild, and transient drug-related adverse event of vitreous floater reported.

本月初的报告表明，其用于青光眼的PER-001玻璃体内植入物耐受性良好，仅报告了一例轻度且短暂的药物相关的玻璃体漂浮物不良事件。

Last year, Sight Sciences’ OMNI surgical system to reduce intraocular pressure in patients with primary open-angle glaucoma

去年，Sight Sciences公司的OMNI手术系统用于降低原发性开角型青光眼患者的眼压。